Evelo Biosciences (Formerly Evelo Therapeutics, VL28)

Evelo Biosciences is at the forefront of developing innovative therapies that modulate the systemic immune response by targeting the gut-body network. The company focuses on creating monoclonal microbials, which are single strains of microbes selected for their specific pharmacological properties. These therapies aim to treat a wide range of diseases, including inflammatory diseases, cancer, autoimmune disorders, metabolic conditions, and neurobehavioral and neuroinflammatory diseases.

Evelo's primary clients include patients suffering from chronic diseases and cancer. The company operates in the biotechnology and pharmaceutical market, leveraging its integrated platform to develop oral biologics. This platform harnesses the central role that cells in the small intestine play in governing immune, metabolic, and neurological systems. The efficiency of this platform has enabled Evelo to produce product candidates for various inflammatory diseases and cancer in a relatively short period.

Evelo's business model revolves around the research, development, and commercialization of these innovative therapies. The company generates revenue through the sale of its product candidates, partnerships, and collaborations with other biotech firms and healthcare institutions.

Keywords: monoclonal microbials, gut-body network, oral biologics, chronic diseases, cancer treatment, immune modulation, inflammatory diseases, autoimmune disorders, metabolic conditions, neuroinflammatory diseases.